Evidence for the Use of Activated Prothrombin Complex Concentrates (aPCCs) in the Treatment of Patients with Haemophilia and Inhibitors

Publisher： Karger

E-ISSN： 1424-8840|32|1|9-12

ISSN： 1424-8832

Source： Pathophysiology of Haemostasis and Thrombosis, Vol.32, Iss.1, 2002-05, pp. : 9-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on‐demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain

By  

HAEMOPHILIA, Vol. 21, Iss. 3, 2015-05 ,pp. : 320-329

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ten‐year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan

By  

HAEMOPHILIA, Vol. 21, Iss. 3, 2015-05 ,pp. : 374-379

John Wiley & Sons Inc

Access to resources Recommend Favorite

Reversal of oral factor Xa inhibitors by prothrombin complex concentrates: a re‐appraisal

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. S1, 2015-06 ,pp. : S187-S194

John Wiley & Sons Inc

Access to resources Recommend Favorite

6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates

By  

Transfusion Medicine and Hemotherapy, Vol. 36, Iss. 6, 2009-12 ,pp. : 409-418

Karger

Access to resources Recommend Favorite

Prothrombin Complex Concentrates for Urgent Anticoagulation Reversal in Patients with Intracranial Haemorrhage

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 36, Iss. 5, 2009-12 ,pp. : 259-265

Karger

Access to resources Recommend Favorite